{"schema":"sb.node.v1","id":"sb:e/e20001c47e40d4b109d5f837","kind":"entity","label":{"text":"immunotherapy","locale":"en"},"identity":{"anchor":"label:en:immunotherapy","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-06T15:55:50.397889+00:00","snapshot":"deploy 13617f67d3e06ad37ec49264ae71ad6a9e140589"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":513,"separatePublishers":141,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-01-01","to":"2026-10-05","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.17: about 83% of mentions carry no typed assertion"]}},"dimensions":{"domains":["oncology","pubmed_targeted","precision_medicine"],"activeDays":130,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/3d84a74738fd05933632af29","kind":"observation","label":"Frontiers Precision Oncology · 2026-10-05 · Editorial: Evolving non-invasive biomarkers: chemokines and multi-omic profiling in NSCLC immunotherapy response","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.2002791"},{"id":"sb:o/4a81158a5099222eaf7d149e","kind":"observation","label":"Seoul Economic Daily - English Edition · 2026-10-02 · Korean Surgeons See Shift to Pre-Surgery Immunotherapy in Stage 2-3 Stomach Cancer","url":"https://en.sedaily.com/technology/2026/10/02/korean-surgeons-see-shift-to-pre-surgery-immunotherapy-in"},{"id":"sb:o/587645ce766454c55f5cae2a","kind":"observation","label":"J Control Release · 2026-10-02 · A systemic-absorption-blocked (SEAL) nanoplatform for mRNA-based local immunotherapy.","url":"https://doi.org/10.1016/j.jconrel.2026.115430"},{"id":"sb:o/abc752df2f99751e956fa259","kind":"observation","label":"News from California, across the nation and world - Los Angeles Times · 2026-10-01 · Your guide to Proposition 38: Immunology and immunotherapy research funding","url":"https://www.latimes.com/california/story/2026-10-01/2026-california-election-proposition-38-immunology-immunotherapy-funding-voter-guide"},{"id":"sb:o/35413ecea0896642063aa0a1","kind":"observation","label":"Future Oncol · 2026-10-01 · SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.","url":"https://doi.org/10.1080/14796694.2026.2736401"},{"id":"sb:o/aed01b0b5b43240d88840443","kind":"observation","label":"J Immunother Cancer · 2026-10-01 · Propionate promotes CD8+ T-cell infiltration and enhances immunotherapy efficacy in colorectal cancer.","url":"https://doi.org/10.1136/jitc-2026-015279"},{"id":"sb:o/30a510568df8a57a111d2650","kind":"observation","label":"Cell Host Microbe · 2026-09-30 · An enzyme-responsive nanoplatform rewires host-microbe tryptophan metabolism for cancer immunotherapy.","url":"https://doi.org/10.1016/j.chom.2026.09.011"},{"id":"sb:o/df01d152953b007a95f43abf","kind":"observation","label":"The Medical News · 2026-09-29 · Blood tests can identify cancer neoantigens for personalized immunotherapy","url":"https://www.news-medical.net/news/20260929/Blood-tests-can-identify-cancer-neoantigens-for-personalized-immunotherapy.aspx"},{"id":"sb:o/2370b918b315466f36fd6242","kind":"observation","label":"Cancer Sci · 2026-09-28 · SLAMF6 Enhances the Efficacy of Anti-PD-L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis.","url":"https://doi.org/10.1111/cas.70530"},{"id":"sb:o/f0d91744031e2de103350c06","kind":"observation","label":"The ASCO Post · 2026-09-28 · Adding Targeted Immunotherapy to Pembrolizumab in Recurrent or Metastatic HPV16-Positive Head and Neck Squamous Cell Carcinoma","url":"https://ascopost.com/news/september-2026/adding-targeted-immunotherapy-to-pembrolizumab-in-recurrent-or-metastatic-hpv16-positive-head-and-neck-squamous-cell-carcinoma/"}],"cursor":"c1.eyJpZCI6InNiOmUvZTIwMDAxYzQ3ZTQwZDRiMTA5ZDVmODM3IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA2VDE1OjU1OjUwLjM5Nzg4OSswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":11,"byKind":{"claim":1,"co-mentioned":10},"items":[{"id":"sb:p/467f407a99839c93f45d014f","kind":"claim","label":"Propionate promotes CD8+ T-cell infiltration and enhances immunotherapy efficacy in colorectal cancer — single source","role":"named-in","relationKind":"claim","members":1},{"kind":"relation","label":"co-mentioned with colorectal cancer (259 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/0725cc3ec034d8655a343f00"},{"kind":"relation","label":"co-mentioned with fda (84 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7452689d97c7c885406e799d"},{"kind":"relation","label":"co-mentioned with lung cancer (82 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/27c8d6ca13365be381edf726"},{"kind":"relation","label":"co-mentioned with ai (82 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b4153e66ecd99644a79e3a27"},{"kind":"relation","label":"co-mentioned with china (64 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/eb9e3f039eba6f25b268eee0"},{"kind":"relation","label":"co-mentioned with msi-h (56 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9590e48ade33dc09374bd339"},{"kind":"relation","label":"co-mentioned with t-cell (56 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/90bb905c886825b7846113cc"},{"kind":"relation","label":"co-mentioned with clinical trial (55 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9484f7f975002eb0509f095e"},{"kind":"relation","label":"co-mentioned with united states (53 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7f625dc38e524712ec265468"}],"cursor":"c1.eyJpZCI6InNiOmUvZTIwMDAxYzQ3ZTQwZDRiMTA5ZDVmODM3IiwibCI6InJlbGF0aW9ucyIsIm8iOjEwLCJrIjpudWxsLCJhIjoiMjAyNi0xMC0wNlQxNTo1NTo1MC4zOTc4ODkrMDA6MDAifQ","order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/e20001c47e40d4b109d5f837","mcp":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\"}","page":"/entity/immunotherapy/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}